JPH09249578A - Clinical application of crude drug extract using tyrosinase activity as index - Google Patents
Clinical application of crude drug extract using tyrosinase activity as indexInfo
- Publication number
- JPH09249578A JPH09249578A JP8060910A JP6091096A JPH09249578A JP H09249578 A JPH09249578 A JP H09249578A JP 8060910 A JP8060910 A JP 8060910A JP 6091096 A JP6091096 A JP 6091096A JP H09249578 A JPH09249578 A JP H09249578A
- Authority
- JP
- Japan
- Prior art keywords
- fructus
- crude drug
- drug extract
- crude drugs
- crude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【0001】[0001]
【発明の属する技術】本発明は下表56種の生薬抽出物
の1種又は2種以上を使用するチロシナーゼ賦活剤、及
びその少なくとも1つ以上を配合する抗白斑治療剤及び
(又は)抗白髪治療剤に関する。これらの生薬名を表1
に列挙する。TECHNICAL FIELD The present invention relates to a tyrosinase activator using one or more of the following 56 herbal extracts, and an anti-white spot therapeutic agent and / or anti-white hair containing at least one of them. Regarding therapeutic agents. Table 1 shows the names of these crude drugs
Are listed.
【表1】 [Table 1]
【表2】 [Table 2]
【表3】 [Table 3]
【0002】[0002]
【従来の技術】本発明者らはさきにカフェ酸(Caffeic
acid) 及びその誘導体がチロシナーゼ活性化作用を有
し、抗白斑治療と抗白髪治療に有効なことを発見した。
しかしながら、これらは下記のような短所のあることも
見出された。そこで、本発明者らは更に有効な治療薬の
開発を目ざした。2. Description of the Related Art The present inventors have previously described caffeic acid.
acid) and its derivatives have a tyrosinase activating effect and are effective for the treatment of anti-white spots and anti-hair graying.
However, they were also found to have the following disadvantages. Therefore, the present inventors have aimed to develop a more effective therapeutic drug.
【0003】[0003]
【発明が解決しようとする課題】カフェ酸或いはクロロ
ゲン酸(Chlorogenic acid) 及びそれらの誘導体のチロ
シナーゼ賦活作用には一定濃度間には濃度━作用曲線が
求められるが、ある濃度以上では却って作用が減少す
る。即ち作用に極大値が存在し、更に強力な作用を求め
ることができない。その隘路を打開するために、この開
発を企図した。[Problems to be Solved by the Invention] For the tyrosinase activating effect of caffeic acid or chlorogenic acid (Chlorogenic acid) and their derivatives, a concentration-action curve is required between certain concentrations, but the action decreases rather than a certain concentration. To do. That is, there is a maximum value in the action, and a stronger action cannot be obtained. This development was intended to break the bottleneck.
【0004】[0004]
【課題を解決するための手段】生薬の抽出物は幾多の複
雑な成分を含有しており、それら成分の個々の作用とは
異なった作用或いは個々の作用を遙かに凌駕する強力な
作用を呈することが知られている。この経験に基づき、
生薬の抽出物のチロシナーゼ賦活作用に目を向けた。生
薬の中には、カフェ酸、クロロゲン酸及びそれらの誘導
体を有するものが多数知られている。そしてこれら抽出
物のチロシナーゼ賦活作用が、カフェ酸やクロロゲン酸
或いはその誘導体の作用では説明できない程強力なもの
が存在することを発見し、本発明を完成した。[Means for Solving the Problems] Extracts of crude drugs contain a number of complex components, and have a different action from the individual actions of these components or a powerful action far exceeding the individual actions. It is known to present. Based on this experience
We turned to the tyrosinase activating action of extracts of crude drugs. Many crude drugs having caffeic acid, chlorogenic acid and their derivatives are known. The present inventors have completed the present invention by discovering that the tyrosinase activating action of these extracts is so strong that it cannot be explained by the action of caffeic acid, chlorogenic acid or its derivatives.
【0005】[0005]
【発明の実施形態】本発明の実施形態をかかげて本発明
を具体的に説明する。BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be specifically described with reference to the embodiments of the present invention.
【0006】実施例1 チロシナーゼ賦活作用の測定系を表2の如く設定した。
チロシナーゼはマッシュルーム(mushroom) 由来のシグ
マ(Sigma)社製を使用した。Example 1 A measurement system for tyrosinase activation activity was set as shown in Table 2.
As tyrosinase, mushroom-derived Sigma manufactured by Sigma was used.
【0007】[0007]
【表4】 *Ec:対照吸光度(Control absorbance) at A475,A580nm A2min.-A0min. Es:試料吸光度 at A475,A580nm A2min.-A0min. [Table 4] * Ec: Control absorbance at A475, A580nm A2min.-A0min. Es: Sample absorbance at A475, A580nm A2min.-A0min.
【0008】実施例2 カフェ酸・クロロゲン酸の誘導体を含有する生薬エキス
のチロシナーゼ賦活作用を測定した。その一部は図1に
グラフとして総括した。抽出は50%エタノール、10
0%エタノール、酢酸エチルの3溶媒によって行った。
全ての生薬について50%エタノールによる抽出物が最
も有効であった。Example 2 The tyrosinase activating effect of a crude drug extract containing a derivative of caffeic acid / chlorogenic acid was measured. A part of them is summarized as a graph in FIG. Extraction is 50% ethanol, 10
It was carried out with 3 solvents of 0% ethanol and ethyl acetate.
The extract with 50% ethanol was the most effective for all crude drugs.
【0009】実施例3 これら生薬エキスの賦活作用とカフェ酸及びクロロゲン
酸の賦活作用を比較した。そして仮説は実証された。
〔表3〕参照。Example 3 The activating effect of these crude drug extracts was compared with that of caffeic acid and chlorogenic acid. And the hypothesis was substantiated.
See [Table 3].
【0010】[0010]
【表5】 *試料濃度は全て0.1%とした。[Table 5] * All sample concentrations were 0.1%.
【0011】実施例4 以下の処方により、抗白毛症治療薬を調製した。 <トニック> 連翹50%エタノールエキス 0.5% 塩化カルプロニウム 1.0% ニコチン酸ベンジル 0.05% 50%エタノール/緩衝液* 適量 全量 100ml *クエン酸ナトリウム・HCl 緩衝液 (pH4.8〜5.0)Example 4 An anti-alcoholic disease therapeutic agent was prepared according to the following formulation. <Tonic> Continuous 50% ethanol extract 0.5% Carpronium chloride 1.0% Benzyl nicotinate 0.05% 50% Ethanol / buffer * Proper amount 100ml * Sodium citrate / HCl buffer (pH 4.8 ~ 5.0)
【0012】実施例5 以下の処方により、抗白毛症治療剤を調製した。 <トニック> 迷迭香50%エタノールエキス または夏枯草エキス 0.5% ニコチン酸ベンジル 0.05% センブリエキス 0.1% 側柏葉エキスA 0.1% (塩化カルプロニウム 0.1% ) 50%エタノール/緩衝液* 適量 全量 100ml *クエン酸ナトリウム/HCl 緩衝液 (pH4.8〜5.0)Example 5 An anti-baldew treatment agent was prepared according to the following formulation. <Tonic> Labyrinth 50% ethanol extract or summer hay extract 0.5% Benzyl nicotinate 0.05% Cemblyx extract 0.1% Side Kashiwa leaf extract A 0.1% (Carpronium chloride 0.1%) 50% Ethanol / buffer * Proper amount 100ml * Citric acid Sodium / HCl buffer (pH 4.8 ~ 5.0)
【0013】実施例6 以下の処方により、抗白斑治療薬を調製した。 <液剤> 連翹又は迷迭香50%エタノールエキス 0.5% 塩化カルプロニウム 3〜5.0% 1,3-ブチレングリコール 40.0% 20%エタノール/緩衝液* 適量 全量 100ml *クエン酸ナトリウム/HCl 緩衝液 (pH4.8〜5.0)Example 6 An anti-white spot therapeutic agent was prepared according to the following formulation. <Liquid formulation> 50% ethanol extract or 0.5% carpronium chloride 3 to 5.0% 1,3-butylene glycol 40.0% 20% ethanol / buffer solution * Proper amount 100 ml * Sodium citrate / HCl buffer solution (pH 4.8) ~ 5.0)
【0014】実施例7 以下の処方により、抗白斑症治療薬を調製した。 <軟膏> 連翹又は迷迭香50%エタノールエキス 0.5g 塩化カルプロニウム 3.0g 1,3-ブチレングリコール 20.0g 親水ポロイド 適量 全量 100gExample 7 An anti-white spot disease therapeutic agent was prepared according to the following formulation. <Ointment> 50% ethanol extract with continuous scent or camouflage scent 0.5g Carpronium chloride 3.0g 1,3-Butylene glycol 20.0g Hydrophilic poloid 100g
【図1】実施例における生薬エキスのチロシナーゼ賦活
作用測定結果をグラフとして示した図である。FIG. 1 is a graph showing the results of measuring the tyrosinase activation effect of crude drug extracts in Examples.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 35/78 A61K 35/78 J K N Q S T V ADA ADAH ADS ADSR 7/00 7/00 K X 7/06 7/06 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 6 Identification number Internal reference number FI Technical indication location A61K 35/78 A61K 35/78 J K N Q S T V ADA ADAH ADS ADSR 7/00 7/00 K X 7/06 7/06
Claims (2)
る下記56種の生薬の抽出物: 【外1】 1. Extracts of the following 56 kinds of crude drugs having tyrosinase activating action as a powerful property: [External 1]
種以上を含有することを特徴とする抗白斑及び(又は)
抗白髪治療剤。2. One or two of the crude drug extracts according to claim 1.
Anti-white spot and / or containing at least one species
Anti-grey hair treatment agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8060910A JPH09249578A (en) | 1996-03-18 | 1996-03-18 | Clinical application of crude drug extract using tyrosinase activity as index |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8060910A JPH09249578A (en) | 1996-03-18 | 1996-03-18 | Clinical application of crude drug extract using tyrosinase activity as index |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09249578A true JPH09249578A (en) | 1997-09-22 |
Family
ID=13156013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8060910A Pending JPH09249578A (en) | 1996-03-18 | 1996-03-18 | Clinical application of crude drug extract using tyrosinase activity as index |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH09249578A (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041183A1 (en) * | 1997-03-19 | 1998-09-24 | Shiseido Company, Ltd. | Dermatologic preparations for beautifying |
KR20000045573A (en) * | 1998-12-30 | 2000-07-25 | 유상옥 | Anti-oxidant cosmetic composition containing the extract of forsythia fructus |
JP2001002575A (en) * | 1999-06-21 | 2001-01-09 | Sunstar Inc | Accelerator for accelerating production of melanine |
JP2001288052A (en) * | 2000-04-10 | 2001-10-16 | Maruzen Pharmaceut Co Ltd | Promotor for tyrosinase activity and gray hair- ameliorating agent |
JP2002003381A (en) * | 2000-06-26 | 2002-01-09 | Kao Corp | Melanin production accelerator |
FR2828399A1 (en) * | 2001-08-07 | 2003-02-14 | Soc Extraction Principes Actif | Composition useful for combating skin aging and reducing wrinkles comprises an extract of dates |
US6627623B2 (en) * | 2001-02-21 | 2003-09-30 | Rutgers, The State University | Inducing cell apoptosis and treating cancer using 1-O-acetylbritannilactone or 1,6-O,O-diacetylbritannilactone |
KR100570118B1 (en) * | 1998-12-30 | 2006-07-27 | 주식회사 코리아나화장품 | Antioxidant Cosmetics Containing Allium Extract |
KR100570120B1 (en) * | 1998-12-30 | 2006-07-27 | 주식회사 코리아나화장품 | Free radical scavenging cosmetics containing hawthorn extract |
WO2008115583A1 (en) * | 2007-03-21 | 2008-09-25 | John Mini | Herbal treatments |
US7524518B2 (en) | 2001-05-11 | 2009-04-28 | Kim Sung-Jin | Composition for promoting regeneration of hard tissues comprising an extract of cortex eucommiae |
CN103142738A (en) * | 2013-04-07 | 2013-06-12 | 贵州鸿德中药开发有限公司 | Traditional Chinese medicine for treating bad cold |
KR101312965B1 (en) * | 2011-05-20 | 2013-09-27 | 이상록 | The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao |
CN104771434A (en) * | 2014-01-13 | 2015-07-15 | 吕圭源 | Radish seed-chrysanthemum combined extract and use thereof |
KR20160063401A (en) * | 2013-10-16 | 2016-06-03 | 레거시 헬스케어 리미티드 | Use of a composition for the pigmentation of hair and hairs |
JP2016537350A (en) * | 2013-11-19 | 2016-12-01 | ディーエスエム アイピー アセッツ ビー.ブイ. | Use of Edelweiss extract in hair care to prevent graying |
CN109846959A (en) * | 2019-04-03 | 2019-06-07 | 安福县灵奕科技有限公司 | A kind of Chinese medicine composition for treating leucoderma |
-
1996
- 1996-03-18 JP JP8060910A patent/JPH09249578A/en active Pending
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041183A1 (en) * | 1997-03-19 | 1998-09-24 | Shiseido Company, Ltd. | Dermatologic preparations for beautifying |
KR20000045573A (en) * | 1998-12-30 | 2000-07-25 | 유상옥 | Anti-oxidant cosmetic composition containing the extract of forsythia fructus |
KR100570118B1 (en) * | 1998-12-30 | 2006-07-27 | 주식회사 코리아나화장품 | Antioxidant Cosmetics Containing Allium Extract |
KR100570120B1 (en) * | 1998-12-30 | 2006-07-27 | 주식회사 코리아나화장품 | Free radical scavenging cosmetics containing hawthorn extract |
JP2001002575A (en) * | 1999-06-21 | 2001-01-09 | Sunstar Inc | Accelerator for accelerating production of melanine |
JP2001288052A (en) * | 2000-04-10 | 2001-10-16 | Maruzen Pharmaceut Co Ltd | Promotor for tyrosinase activity and gray hair- ameliorating agent |
JP2002003381A (en) * | 2000-06-26 | 2002-01-09 | Kao Corp | Melanin production accelerator |
US6627623B2 (en) * | 2001-02-21 | 2003-09-30 | Rutgers, The State University | Inducing cell apoptosis and treating cancer using 1-O-acetylbritannilactone or 1,6-O,O-diacetylbritannilactone |
US7524518B2 (en) | 2001-05-11 | 2009-04-28 | Kim Sung-Jin | Composition for promoting regeneration of hard tissues comprising an extract of cortex eucommiae |
FR2828399A1 (en) * | 2001-08-07 | 2003-02-14 | Soc Extraction Principes Actif | Composition useful for combating skin aging and reducing wrinkles comprises an extract of dates |
WO2003013463A1 (en) * | 2001-08-07 | 2003-02-20 | Societe D'extraction Des Principes Actifs (Vincience Sa) | Use of date stone extract for treating aging skin |
WO2008115583A1 (en) * | 2007-03-21 | 2008-09-25 | John Mini | Herbal treatments |
KR101312965B1 (en) * | 2011-05-20 | 2013-09-27 | 이상록 | The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao |
CN103142738A (en) * | 2013-04-07 | 2013-06-12 | 贵州鸿德中药开发有限公司 | Traditional Chinese medicine for treating bad cold |
KR20160063401A (en) * | 2013-10-16 | 2016-06-03 | 레거시 헬스케어 리미티드 | Use of a composition for the pigmentation of hair and hairs |
JP2016533371A (en) * | 2013-10-16 | 2016-10-27 | レガシー ヘルスケア リミテッド | Use of compositions for pigmentation of hair |
US11219592B2 (en) * | 2013-10-16 | 2022-01-11 | Legacy Healthcare (Switzerland) Sa | Use of a composition for the pigmentation of hair and hairs |
JP2016537350A (en) * | 2013-11-19 | 2016-12-01 | ディーエスエム アイピー アセッツ ビー.ブイ. | Use of Edelweiss extract in hair care to prevent graying |
CN104771434A (en) * | 2014-01-13 | 2015-07-15 | 吕圭源 | Radish seed-chrysanthemum combined extract and use thereof |
CN109846959A (en) * | 2019-04-03 | 2019-06-07 | 安福县灵奕科技有限公司 | A kind of Chinese medicine composition for treating leucoderma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09249578A (en) | Clinical application of crude drug extract using tyrosinase activity as index | |
CN102552579B (en) | Traditional Chinese medicine composition for treating hyperlipemia fatty liver, as well as preparation method, quality detection method and application thereof | |
CN1203871C (en) | Medicine for treating diseases of digestive system | |
Kapahi et al. | Traditional medicinal plants of Gurez (Kashmir)–an ethnobotanical study | |
DE202019102955U1 (en) | Water-soluble beverage powder | |
CN108852998A (en) | Improve active component, face mask cream and the preparation method of hormone face, lead mercury poisoning face | |
CN105998652A (en) | Traditional Chinese medicine composition and application and preparation thereof | |
JP2007016053A (en) | Antineoplastic agent | |
CN110755592A (en) | Traditional Chinese medicine composition for hair growth and hair nourishing, and preparation method and application thereof | |
CN1056064C (en) | Medicine for curing liver cancer and its making method | |
JPH0217117A (en) | Hair tonic | |
Bergner | Antiviral botanicals in herbal medicine | |
CN103784373A (en) | Traditional Chinese medicine whitening mask manufacturing method | |
CN111096938B (en) | Traditional Chinese medicine extract containing emilia sonchifolia and application of traditional Chinese medicine extract in preparation of skin care products | |
JPH0212447B2 (en) | ||
CN108379133A (en) | Chinese medicine cosmetics and skincare product | |
JPH01261322A (en) | Hair rearing agent | |
CN112773879A (en) | Traditional Chinese medicine composition for growing and nourishing hair and preparation thereof | |
CN104509615A (en) | Hawthorn liver-protective tea | |
CN1058395C (en) | Inhalant for prevention and treatment of baldness | |
CN103211909A (en) | Traditional Chinese medicine composition for treating dandruff | |
CN1168481C (en) | Xin-nao-ning capsule for treating cardio-vascular and cerebral vascular disease | |
CN1169286A (en) | Ointment of quickly removing acne without blackspot | |
CN1193528A (en) | Capsules for paralysis and preparation thereof | |
Awang | Standardization of herbal medicinal products |